Bridging the gap between innovation and capital
Medical Excellence Capital
Focus on Biotech Therapeutic Companies
Program
Medical Excellence Capital (MED) is an early-stage, life sciences venture capital firm with a focus on precision medicine. With $300M under management, they are actively investing out of our second fund.
Event
LaunchBio, Citrin Cooperman, and Silicon Valley Bank, a division of First Citizens Bank, with support by Fondation Ipsen, are pleased to announce their next Investor Connect virtual event with Medical Excellence Capital (MEC).
Areas of current high interest include inflammation & immunology, allergy, cardiovascular disease, precision oncology, and neuropsychiatry. MEC focuses on Seed to Series A opportunities and prefers to lead and co-lead rounds and take active board roles in portfolio companies. MEC is primarily focused on therapeutics and typically engages at the DC stage or later. They occasionally consider diagnostics and tools opportunistically, though the bar for non-therapeutics investments is very high.
Applications will be selected based on meeting the following criteria:
Geography
Open to investments in USA, North America
Company type
Early-stage biotech companies
Modalities of Interest
- Biologics
- Gene therapies
- Protein-based therapies
- RNA-based therapeutics
- Small molecule
Therapeutic areas include, but are not limited to:
- Cardiology
- Endocrinology
- Gastroenterology
- Hematology
- Immunology
- Neurology
- Oncology
- Ophthalmology
- Pulmonology
Stage
Companies seeking funding for Seed and Series A
Qualifying start-ups can apply here today.
Applications are accepted on a rolling basis. Learn more about LaunchBio’s Investor Connect series, in partnership with Citrin Cooperman and Silicon Valley Bank, a division of First Citizens Bank.